FDA Warning Letters Hit Inadequate Investigations and QC Failings
This article was originally published in The Gold Sheet
Executive Summary
In recent warning letters, FDA continued to hammer manufacturers for inadequate investigation of out-of-specification results and lax oversight of manufacturing operations by quality control units.